Shruti Bhat PhD, MBA, Lean Six Sigma Black Belt
  • Home
  • About Shruti
  • Consulting
  • Workshops
  • Patents
  • Articles
    • Case Studies
    • Innovation Portfolio Development & Patents
    • Drugs-in-the- making
    • Culture Change & Business Transformation
    • Operational Excellence, Quality & Continuous Improvement
  • Books
  • Digital
  • Blog
  • Videos
  • Contact

FDA Devising New Guidelines To Expedite Testing, Approval Of Multidrug Regimens

3/21/2010

0 Comments

 
Here are some highlights from current pharma and clinical research news, views and data- 

FDA Devising New Guidelines To Expedite Testing, Approval Of Multi-drug Regimens.  The Wall Street Journal reported that the FDA is creating new guidelines aimed at expediting the testing and approval process for multi-drug regimens that include new, experimental drugs for some deadly diseases. The agency normally requires each treatment in a drug cocktail to be tested and approved separately. FDA Commissioner Margaret Hamburg said the move "represents a bigger issue -- the strengthening of regulatory science" to include scientific advances.

Insulin patch is on track for clinical trials. 

Phosphagenics Limited’ s TPM (Targeted Penetration Matrix) insulin project should begin human trials in the first half of 2010. For this product, the company has adapted the patch technology that it had developed for its oxycodone program. The company also has achieved dose optimization that reduces substantially the amount of insulin required for a therapeutic dose and has demonstrated through tests on animals that the product lowers glucose levels. 

New Study Aims To Identify Effective Breast Cancer Treatments Quickly. 

"Breast cancer researchers say they could cut years off the time required to test new drugs for treating certain kinds of tumors under a study about to begin at the University of Minnesota and the Mayo Clinic." The study is designed to help researchers "quickly identify which drugs are effective for different groups of patients, based on the genetic or molecular makeup of their tumors." The "drugs that show no benefit can be quickly dropped, without wasting years and millions of dollars on further study."  

Three companies have joined the government in the "$26 million trial set to last five years," The trial includes five drugs, which "the FDA is now involved in fast-tracking...but says it is important to find the right drug for the right patient." Dr. Anna Barker, deputy director of the National Cancer Institute, "says that as a result" of the study, "life-saving drugs will get to patients much faster."  

There are reports that patients will be matched to the drugs based on their DNA, and the drug-makers agreed to share information on predicting patient response using their genes. The study will include Abbott Laboratories' veliparib, Amgen's conatumumab and AMG 386, and Pfizer Inc.'s figitumumab and neratinib.  
 
Different Pediatric Asthma Cases Do Best With Different Step-Up Treatments. 

Researchers at the University of Wisconsin have discovered that "different kids do best with different step-up treatments" once they find that their "regular steroid inhaler fails to prevent asthma attacks."  

According to the paper in the New England Journal of Medicine, the "drugs with the best chance of success -- 45% -- are long-acting beta-agonists," however, "safety concerns limit the use of these agents." Investigators also discovered that approximately "30% of kids...do best either with a leukotriene-receptor antagonist, or by doubling the dose of the child's current inhaled steroid medication," but there is "no clear winner," and "there were few clues to predict which kids were most likely to do best on which step-up treatment."  
​Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement

    New Book Released!

    top ten strategic decision-making tools for operational excellence

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    5S
    Agile
    Artificial Intelligence
    Automation
    Balanced Score Card
    Biotechnology
    Books
    Business Turnaround
    Case Studies
    Change Management
    Chemical Industry
    CMMI
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Food Industry
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    Nanotechnology
    Operations
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    Robotics
    Scrum
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    TQM
    Videos
    Voice Of Customer
    Workshops

    Shruti's books...

    Picture
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    Picture
    how to overcome challenges of creating effective teams
    how to lead a successful business transformation

    ​Micro-Learning
    ​Partner

    Picture

    Publishing Partner

    fast read books, business management books, health and wellness books, spiritual guidance books, best online book store

    Wellness
    ​Partner

    Picture
© Copyright 1992- 2022 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media